All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results Terminated | 2004-000361-35 | A 12-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON'S DISEASE WITH "WEARING OFF" MOTOR FLUCTUATIONS AND... | 2008-04-10 | due-trials |
Reported results | 2004-000774-31 | An open-label, randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast cancer... | 2006-09-21 | due-trials |
Reported results | 2004-001162-40 | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognit... | 2006-10-20 | due-trials |
Completed, but no date, and reported results | 2004-002597-33 | An open label dose adjustment and phase II study of E7070 in combination with capecitabine: Part 1: to determine the recommended dose of the combination Part 2: to determine the efficacy of the comb... | bad-data | |
Completed, but no date, and reported results | 2004-003355-39 | A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia. | bad-data | |
Reported results | 2005-000260-57 | Randomized trial to assess efficacy and safety of an add-on treatment with zonisamide in adults with focal epileptic seizures with or without secondary generalization | 2008-02-27 | due-trials |
Reported results | 2005-001982-33 | An Open Label Study of ZONEGRANTM Zonisamide in patients with partial onset seizures | 2007-08-03 | due-trials |
Reported results | 2005-003656-35 | A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to th... | 2009-10-15 | due-trials |
Reported results | 2005-004009-26 | A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines ... | 2018-01-16 | due-trials |
Reported results | 2005-004199-18 | A Double-blind, Placebo-controlled, Dose-escalation, Parallel Group Study of E2007 given as Adjunctive Therapy in Patients with Refractory Partial Seizures | 2007-02-06 | due-trials |
Reported results | 2005-004271-37 | A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory Prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy... | 2010-02-18 | due-trials |
Reported results | 2005-004272-20 | Phase II Study of E7389 Administered as an IV Infusion Day 1 and 8 every 3 Weeks in Pretreated Patients with Advanced and/or Metastatic Soft Tissue Sarcoma | 2012-06-28 | due-trials |
Reported results | 2005-004293-24 | A 14-Month Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 as an Adjunctive Therapy in Patients With Refractory Partial Seizures | 2014-07-01 | due-trials |
Reported results | 2005-004314-33 | A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctua... | 2007-08-23 | due-trials |
Reported results | 2005-004503-11 | Randomized Phase 3 Trial of Decitabine Versus Patient's Choice with Physician's Advice of Either Supportive Care or Low-dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute M... | 2013-05-27 | due-trials |
Reported results | 2005-005537-35 | A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis | 2010-10-28 | due-trials |
Reported results | 2005-006029-94 | A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease | 2009-08-14 | due-trials |
Reported results | 2006-000156-40 | "Estudio aleatorizado, multicéntrico, doble ciego, para comparar la eficacia y seguridad de zonisamida y carbamazepina como monoterapia en pacientes con epilepsia parcial recién diagnosticada" (A ran... | 2011-01-14 | due-trials |
Reported results | 2006-000296-15 | A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Clinical Events and Biomarkers in Patients with Non-ST-Segment Elevation Acute Coronary... | 2009-06-09 | due-trials |
Reported results | 2006-001949-34 | A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus Treatment of Physician's Choice' in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously Tr... | 2013-05-31 | due-trials |
Reported results | 2006-002339-26 | A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Flu... | 2008-07-30 | due-trials |
Reported results | 2006-002515-27 | A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizures | 2011-03-15 | due-trials |
Reported results | 2006-002516-10 | A randomised, double blind, placebo-controlled study to evaluate the safety and tolerability and to explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial sei... | 2010-11-23 | due-trials |
Reported results | 2006-002937-20 | A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients wi... | 2008-06-18 | due-trials |
Reported results | 2006-003702-26 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients with Refractory Partial Seizures | 2008-01-15 | due-trials |
Reported results | 2006-004888-54 | Double-Blind, Parallel-Group Comparison of 23 mg Donepezil SR to 10 mg Donepezil IR in Patients with Moderate to Severe Alzheimers disease | 2009-03-27 | due-trials |
Reported results | 2006-004890-93 | E2020-G000-328 Estudio de extensión abierto de donepezilo LP 23 mg en pacientes con enfermedad de Alzheimer moderada o grave. Open-Label Extension Study of 23 mg Donepezil SR in Patients with Mode... | 2010-04-01 | due-trials |
Reported results | 2006-006488-22 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients with Painful Diabetic Neuropathy | 2008-07-11 | due-trials |
Reported results | 2007-000198-53 | An open-label extension study following a double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizur... | 2012-03-08 | due-trials |
Reported results | 2007-000801-30 | A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Flu... | 2008-06-27 | due-trials |
Reported results | 2007-003556-10 | A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in myoclonic seizures associated with idiopathic generalised epilepsy. | 2009-01-05 | due-trials |
Reported results | 2007-003557-91 | A double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of adjunctive zonisamide in primary generalised tonic clonic seizures | 2009-01-28 | due-trials |
Reported results | 2007-005313-19 | A multicentre, randomised, active comparator, parallel group study to compare the effect on cognition of adjunctive therapy with zonisamide versus sodium valproate. | 2008-12-08 | due-trials |
Reported results | 2007-005435-28 | Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment | 2009-09-18 | due-trials |
Reported results | 2007-005442-20 | Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment | 2009-05-22 | due-trials |
Reported results | 2007-005495-13 | A Multi-Center, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 (Perampanel) in Patients with Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neural... | 2009-11-12 | due-trials |
Reported results | 2007-005570-32 | A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Diseas... | 2009-09-14 | due-trials |
Reported results | 2007-005933-12 | Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified b... | 2019-02-18 | due-trials |
Reported results | 2007-006046-17 | A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Diseas... | 2009-09-10 | due-trials |
Reported results | 2007-006168-31 | A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel- Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial ... | 2011-02-12 | due-trials |
Reported results | 2007-006169-33 | A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel- Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Sei... | 2010-06-09 | due-trials |
Reported results | 2007-006170-28 | A 14-Month Open-Label Extension Phase of the Double-Blind, Placebo- Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive T... | 2014-09-18 | due-trials |
Trial is outside EEC, and reported results | 2007-006191-11 | A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seiz... | bad-data | |
Completed, but no date Terminated | 2007-006695-10 | Open Label Extension Study Following Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Adjunctive Zonisamide in Primary Generalized Tonic-Clonic Seizures | bad-data | |
Completed, but no date Terminated | 2007-006696-36 | Open label Extension Study Following Double-blind, Randomized, Placebo-controlled, Multicentre Study to Assess Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures associated with Idiopa... | bad-data | |
Reported results | 2008-001159-23 | A Randomized, Double-Blind Extension Study to Assess the Long-Term Safety and to Explore the Long-Term Efficacy of Zonisamide as Monotherapy in Newly Diagnosed Partial Seizures | 2011-07-26 | due-trials |
Reported results | 2008-002843-18 | A 2-year, Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor... | 2013-01-10 | due-trials |
Reported results | 2008-005236-32 | Dalteparin Sodium Injection (Fragmin®), Multicenter, Open Label, Single-arm, Long Term (52 weeks) Study for Understanding Safety and Efficacy in Subjects with Malignancies and Symptomatic Venous Throm... | 2012-03-15 | due-trials |
Reported results | 2008-005872-29 | A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum... | 2013-01-25 | due-trials |
Completed, but no date, and reported results | 2009-010895-64 | A superiority, randomized, open-label, multi-center study to compare the efficacy and safety of adjunctive zonisamide vs replacement with zonisamide of the last added antiepileptic drug in patients wi... | bad-data | |
Exempt, with results | 2009-011217-24 | A Phase 1b/2, Multicenter, Open-label, Dose-escalation and Confirmation Study of Eribulin in Combination with Capecitabine | 2015-10-13 | not-yet-due |
Reported results | 2009-014815-11 | A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects with Psoriasis Vulgaris | 2010-12-11 | due-trials |
Exempt, with results | 2009-016047-19 | An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination with Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients with Advanced Non-S... | 2015-05-18 | not-yet-due |
Exempt, with results Terminated | 2009-016050-41 | An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Carboplatin + Gemcitabine versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients with Platinum... | not-yet-due | |
Reported results | 2009-016858-41 | An Open-Label, Single-Arm, Multicenter Phase 2 Study of E7080 in Subjects with Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy | 2015-10-10 | due-trials |
Completed, but no date, and reported results | 2009-017671-22 | An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available Therapies | bad-data | |
Reported results | 2010-018518-56 | A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pha... | 2014-09-01 | due-trials |
Exempt, with results | 2010-019484-10 | An open-label, multicenter Phase Ib/2 study of E7080 alone, and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-target... | 2018-02-08 | not-yet-due |
Reported results | 2010-019526-14 | An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma | 2014-12-01 | due-trials |
Exempt Terminated | 2010-020204-30 | A Multicenter, Open-label, Sequential, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy or Eritoran in Descending Age Groups of Pediatric Subj... | 2011-02-09 | not-yet-due |
Trial is partly outside EEC, and reported results | 2010-023505-36 | A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to ... | 2015-11-02 | bad-data |
Reported results | 2010-023783-41 | A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I- Refractory Differentiated Thyroid Cancer Studio di Fase 3, multicentrico, randomizzato, in doppio ciec... | 2019-03-14 | due-trials |
Reported results | 2010-024479-20 | A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study, with an Open-Label Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of E5501 in Subjects wit... | 2014-06-27 | due-trials |
Reported results | 2010-024483-17 | A Randomised, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma. | 2016-08-10 | due-trials |
Reported results | 2011-000265-12 | A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel-group Study with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized... | 2015-10-16 | due-trials |
Reported results | 2011-000724-15 | A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician's Choice in Subjects with Advanced Non-Small Cell Lung Cancer. Studio... | 2016-05-02 | due-trials |
Reported results | 2011-000752-41 | An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Sorafenib versus Sorafenib Alone as First Line Therapy in Patients with Hepatocellular Carcinoma | 2015-06-30 | due-trials |
Exempt, with results | 2011-000773-31 | An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cetuximab versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and N... | 2017-09-04 | not-yet-due |
Exempt, with results Terminated | 2011-000774-58 | An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cisplatin and Capecitabine versus Cisplatin and Capecitabine Alone in Patients with Advanced or Metastatic Solid ... | 2012-06-07 | not-yet-due |
Reported results | 2011-000830-12 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard of Care fo... | 2015-04-09 | due-trials |
Reported results Terminated | 2011-000831-10 | A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 versus Eltrombopag, in Ad... | 2013-01-22 | due-trials |
Trial is outside EEC, and reported results | 2011-001105-28 | An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as a... | bad-data | |
Exempt, with results | 2011-001959-37 | An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combination... | 2015-07-14 | not-yet-due |
Reported results | 2011-002347-10 | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) versus BSC Alone in Patients with Locally Advanced or Metastatic Non-Squamous Non... | 2015-06-27 | due-trials |
Ongoing | 2012-002843-11 | A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Earl... | not-yet-due | |
Listed as ongoing, but also has a completion date and reported results | 2012-002992-33 | A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carc... | 2021-03-10 | bad-data |
Reported results | 2013-000324-34 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Long-Term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events ... | 2018-04-23 | due-trials |
Reported results | 2013-000934-36 | A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Assoc... | 2017-01-30 | due-trials |
Reported results | 2013-000965-34 | A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Assoc... | 2017-01-26 | due-trials |
Completed, but no date, and reported results | 2013-005391-17 | An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 4 years of ... | bad-data | |
Trial is partly outside EEC, and reported results | 2013-005534-38 | Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies | 2022-07-20 | bad-data |
Trial is partly outside EEC, and reported results | 2014-002167-16 | An Open-Label, Multicenter Study with an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension when Administered as an Adjunctive Ther... | 2021-12-06 | bad-data |
Reported results | 2014-002321-35 | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 years of Age With Inadequately Control... | 2021-07-19 | due-trials |
Reported results | 2014-003812-36 | A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylate... | 2020-08-13 | due-trials |
Reported results | 2014-005199-27 | A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will... | 2020-09-08 | due-trials |
Reported results | 2015-001463-39 | A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel-Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder | 2019-01-08 | due-trials |
Completed, but no date, and reported results Terminated | 2015-001929-17 | This is an Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC). Sperimentazione multicentrica di fase 2, in aperto, a braccio singo... | bad-data | |
Reported results | 2015-004347-39 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older with Insomnia Disorder | 2018-01-30 | due-trials |
Listed as ongoing, but also has a completion date | 2016-000916-14 | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of ... | 2023-05-02 | bad-data |
Trial is outside EEC, and reported results | 2016-001878-15 | Single and Multiple Dose Pharmacokinetics and Safety Study of Rabeprazole Sodium in 12 to 16 Year Old Subjects | bad-data | |
Trial is outside EEC, and reported results | 2016-001879-73 | Safety and Efficacy of Rabeprazole in the Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients | bad-data | |
Trial is outside EEC, and reported results | 2016-001894-34 | A Phase 1 Study of Eribulin Mesylate (E7389, IND #116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS), Including Lympho... | bad-data | |
Trial is outside EEC, and reported results | 2016-001896-63 | An Ascending Bioavailability of a New Oral Suspension of E3810 | bad-data | |
Listed as ongoing, but also has a completion date | 2016-002778-11 | A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcin... | 2024-06-30 | bad-data |
Listed as ongoing, but also has a completion date and reported results | 2016-003352-67 | A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors | 2021-05-17 | bad-data |
Reported results | 2016-003928-23 | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease | 2020-01-15 | due-trials |
Reported results | 2016-004128-42 | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease Studio di 24 mesi controllato verso placeb... | 2020-01-14 | due-trials |
Trial is outside EEC, and reported results | 2016-004944-12 | A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures | bad-data | |
Trial is outside EEC, and reported results | 2016-004945-10 | An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects | bad-data | |
Trial is outside EEC, and reported results | 2016-004946-27 | A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down... | bad-data | |
Trial is outside EEC, and reported results | 2016-004947-35 | An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A... | bad-data | |
Trial is outside EEC, and reported results | 2016-004948-11 | A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down... | bad-data | |
Trial is outside EEC, and reported results | 2016-004949-92 | A 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in the Treatment of the Cognitive Dysfunction Exhibited by Children with Down... | bad-data | |
Trial is outside EEC, and reported results | 2016-004950-14 | An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures | bad-data | |
Trial is outside EEC | 2016-004951-55 | A Multicenter, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures | bad-data | |
Trial is outside EEC, and reported results | 2016-004952-30 | A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients | bad-data | |
Trial is outside EEC, and reported results | 2016-004953-34 | A Long Term Extension Study of E2080 in Patients with Lennox-Gastaut Syndrome | bad-data | |
Trial is outside EEC | 2016-004954-13 | A Multi-center, Randomized, Open-label, Parallel-group, Dose-titration, Add-on, Comparative Study in Evaluating the Efficacy and Safety of Zonisamide (Zonegran) and Lamotrigine (Lamictal) for Subjects... | bad-data | |
Trial is outside EEC | 2016-004955-64 | A Multicenter Comparative Trial of Zonisamide and Topiramate as Monotherapy in Epilepsy Patients: Safety for cognitive function | bad-data | |
Trial is outside EEC | 2016-004956-32 | A Multi-center Comparative Trial of Low and High Dose Zonisamide in Children with Newly Diagnosed Epilepsy as Monotherapy | bad-data | |
Trial is outside EEC, and reported results | 2016-004957-33 | Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation | bad-data | |
Trial is outside EEC | 2016-004958-14 | A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy | bad-data | |
Exempt, with results | 2017-000300-26 | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | 2022-07-25 | not-yet-due |
Trial is outside EEC, and reported results | 2017-001180-20 | Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generaliz... | bad-data | |
Reported results | 2017-003306-40 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study with Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhythm... | 2020-04-17 | due-trials |
Completed, report not yet due | 2017-003668-11 | An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored le... | 2023-12-21 | not-yet-due |
Reported results | 2017-003728-64 | A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies | 2020-04-20 | due-trials |
Other | 2017-004387-35 | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Adva... | not-yet-due | |
Trial is outside EEC, and reported results | 2018-001282-17 | A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft... | bad-data | |
Trial is outside EEC, and reported results | 2018-003426-89 | A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled A... | bad-data | |
Ongoing | 2018-004456-38 | An Open-Label Study with Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhoo... | not-yet-due | |
Other | 2018-004739-58 | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease Studio di ... | not-yet-due | |
Exempt | 2019-003600-12 | A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selecte... | not-yet-due | |
Listed as ongoing, but also has a completion date and reported results | 2019-003696-19 | A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescen... | 2023-08-17 | bad-data |
Trial is outside EEC, and reported results | 2019-003734-17 | A Multicenter, Uncontrolled, Open-label Study and Extension Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Patients with Partial Onset Seizures (Including Second... | bad-data | |
Trial is outside EEC, and reported results | 2020-002109-24 | A Double-blind, Placebo-controlled, Parallel-group Study With an Openlabel Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects W... | bad-data | |
Completed, but no date | 2020-004244-28 | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study with an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclin... | bad-data | |
Exempt | 2021-001568-10 | An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors Estudio abierto, multicéntrico, de fase 1b/2 con E7... | not-yet-due | |
Trial is outside EEC, and reported results | 2021-006003-15 | Post-Marketing Surveillance of Fycompa in Korean Patients | bad-data | |
Trial is outside EEC | 2021-006398-41 | A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan | bad-data | |
Trial is outside EEC, and reported results | 2022-003736-77 | A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors | bad-data |